Artiam Bio, Inc. is a biotechnology company that is developing refined type 1 cannabinoid receptor (CB1) antagonists to treat significant diseases. We are accelerating innovation to bring safe and effective treatment options.

We are focused on leveraging our core competency in cannabinoid receptor biology to develop novel, small molecule drugs to help people whose lives are dramatically affected by severe diseases including non-alcoholic steatohepatitis (NASH), Prader Willi Syndrome (PWS), and Cannabis Use Disorder (CUD).

Artiam Bio: From pre-clinical advancements to real-world applications

We seek to bridge existing gaps through innovation and an ambitious commitment to superior science that will translate our pre-clinical advancements into real-world applications. We are on a mission to provide targeted therapies and innovative treatment options for non-alcoholic steatohepatitis (NASH), cannabis use disorder (CUD) and Prader-Willi Syndrome (PWS) using unmatched, clinically proven technologies.

Learn More About Our Targeted Solutions

Type 1 Cannabinoid Receptor (CB1) Antagonists: A pipeline of promising therapeutics

Blockade of CB1 activity is a promising strategy based on both pre-clinical and clinical evidence. By minimizing the risks associated with earlier evolutions of CB1 antagonists, our best-in-class compounds have the unprecedented potential to deliver life-altering outcomes without mind-altering adverse effects.